Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.49 |
| ▸ | FEN1 | P39748 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30545136 | 1.00 | CNR1 (0.56) | CNR1CNR2CYP11B1CYP11B2NPC1 | |
| Formic Acid SCHEMBL30412981 | 0.93 | CYP11B1 (0.50) | CNR1CNR2CYP11B1CYP11B2NPC1 | |
| SCHEMBL5990332 | 0.89 | CYP11B1 (0.51) | CNR1CNR2CYP11B1CYP11B2NPC1 | |
| SCHEMBL15989428 | 0.84 | CYP11B1 (0.53) | CYP11B1CYP11B2NPC1DGAT1KCNH2 | |
| SCHEMBL31359600 | 0.83 | CNR1 (0.63) | CNR1CNR2CYP11B1CYP11B2NPC1 | |
| SCHEMBL15009839 | 0.81 | CYP11B1 (0.50) | CYP11B1CYP11B2NPC1DGAT1KCNH2 | |
| SCHEMBL9809559 | 0.80 | ALOX5 (0.55) | CNR1CNR2ALOX5APFEN1KIF11 | |
| SCHEMBL23326178 | 0.80 | CYP11B1 (0.62) | CYP11B1CYP11B2NPC1DGAT1KCNH2 | |
| SCHEMBL29775352 | 0.80 | CYP11B1 (0.62) | CYP11B1CYP11B2NPC1DGAT1KCNH2 | |
| SCHEMBL26133012 | 0.78 | IL1B (0.57) | CNR1CNR2CYP11B1CYP11B2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-116635029-A | REV-ERB agonists | 圣路易斯大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9586963-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2015-02-05 | — | — | US | disclosed |
| EP-2760866-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | Genfit (FR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045519-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | NR1D1, NR1D2, PER2 | CNR1 202/4885CNR2 381/4885CYP11B1 50/4885 |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | CNR1 202/4885CNR2 381/4885CYP11B1 50/4885 |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | CNR1 202/4885CNR2 381/4885CYP11B1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.